{"transactions":[{"id":981850,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-03T16:28:31.000Z","date":"2025-12-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":69042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-25-055054","document":"wk-form4_1764797309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000162828025055054/wk-form4_1764797309.xml","form_type":"4"}},{"id":981849,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-12-03T16:28:31.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":45.02,"value":225100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $45.02 per share. The range of sale prices on\nthe transaction date was $44.59 to $45.51. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":66837,"source":{"system":"sec-edgar","filing":"0001628280-25-055054","document":"wk-form4_1764797309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000162828025055054/wk-form4_1764797309.xml","form_type":"4"}},{"id":981848,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-12-03T16:28:31.000Z","date":"2025-12-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":16.89,"value":84450.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 567 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":71837,"source":{"system":"sec-edgar","filing":"0001628280-25-055054","document":"wk-form4_1764797309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000162828025055054/wk-form4_1764797309.xml","form_type":"4"}},{"id":1006938,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-05T17:00:09.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":74042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-25-049671","document":"wk-form4_1762380006.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000162828025049671/wk-form4_1762380006.xml","form_type":"4"}},{"id":1006937,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-11-05T17:00:09.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":100,"price":43.27,"value":4327.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $43.27 per share for 100 shares."}],"balance_after":66270,"source":{"system":"sec-edgar","filing":"0001628280-25-049671","document":"wk-form4_1762380006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000162828025049671/wk-form4_1762380006.xml","form_type":"4"}},{"id":1006936,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-11-05T17:00:09.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":4900,"price":42.65,"value":208985.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $42.65 per share. The range of sale prices on\nthe transaction date was $42.14 to $43.09. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":66370,"source":{"system":"sec-edgar","filing":"0001628280-25-049671","document":"wk-form4_1762380006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000162828025049671/wk-form4_1762380006.xml","form_type":"4"}},{"id":1006935,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-11-05T17:00:09.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":16.89,"value":84450.0,"ownership":{"direct":true},"balance_after":71270,"source":{"system":"sec-edgar","filing":"0001628280-25-049671","document":"wk-form4_1762380006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000162828025049671/wk-form4_1762380006.xml","form_type":"4"}},{"id":1024887,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-03T16:41:29.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":79042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001658247-25-000013","document":"wk-form4_1759524085.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000165824725000013/wk-form4_1759524085.xml","form_type":"4"}},{"id":1024886,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-10-03T16:41:29.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":41.81,"value":209050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $41.81 per share. The range of sales prices on\nthe transaction date was $41.34 to $42.16 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":66270,"source":{"system":"sec-edgar","filing":"0001658247-25-000013","document":"wk-form4_1759524085.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000165824725000013/wk-form4_1759524085.xml","form_type":"4"}},{"id":1024885,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-10-03T16:41:29.000Z","date":"2025-10-01","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":16.89,"value":84450.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On September 4, 2025, the Reporting Person filed a Form 4 (the \"Prior Form 4\") which inadvertently reported that, following the transactions reported in the Prior Form 4, the Reporting Person directly owned 96,270 shares of the Issuer's common stock. In fact, the Reporting Person directly owned 66,270 shares of the Issuer's common stock following the transactions reported in the Prior Form 4."}],"balance_after":71270,"source":{"system":"sec-edgar","filing":"0001658247-25-000013","document":"wk-form4_1759524085.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000165824725000013/wk-form4_1759524085.xml","form_type":"4"}},{"id":1048167,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-04T16:30:10.000Z","date":"2025-09-02","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":84042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001948238-25-000009","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000194823825000009/ownership.xml","form_type":"4"}},{"id":1048166,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-09-04T16:30:10.000Z","date":"2025-09-02","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":32.1,"value":160500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $32.10 per share. The range of sales prices on the transaction date was $32.00 to $32.24 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":96270,"source":{"system":"sec-edgar","filing":"0001948238-25-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000194823825000009/ownership.xml","form_type":"4"}},{"id":1048165,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-09-04T16:30:10.000Z","date":"2025-09-02","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":16.89,"value":84450.0,"ownership":{"direct":true},"balance_after":101270,"source":{"system":"sec-edgar","filing":"0001948238-25-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000194823825000009/ownership.xml","form_type":"4"}},{"id":1055887,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-26T16:30:05.000Z","date":"2025-08-22","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":89042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001948238-25-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000194823825000007/ownership.xml","form_type":"4"}},{"id":1055886,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-08-26T16:30:05.000Z","date":"2025-08-22","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":30.43,"value":912900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $30.43 per share. The range of sales prices on the transaction date was $30.00 to $30.98 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."}],"balance_after":66270,"source":{"system":"sec-edgar","filing":"0001948238-25-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000194823825000007/ownership.xml","form_type":"4"}},{"id":1055885,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-08-26T16:30:05.000Z","date":"2025-08-22","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":16.89,"value":506700.0,"ownership":{"direct":true},"balance_after":96270,"source":{"system":"sec-edgar","filing":"0001948238-25-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000194823825000007/ownership.xml","form_type":"4"}},{"id":1059417,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-08-21T16:30:04.000Z","date":"2025-08-20","kind":"sale","planned":true,"acquired":false,"shares":6492,"price":29.18,"value":189436.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $29.18 per share. The range of sales prices on the transaction date was $28.94 to $29.47 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 529 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":66270,"source":{"system":"sec-edgar","filing":"0001948238-25-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000194823825000005/ownership.xml","form_type":"4"}},{"id":1194808,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-03-21T18:34:04.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":127,"price":34.83,"value":4423.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.83 per share. The range of sales prices on the transaction date was $34.78 to $35.00 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":72233,"source":{"system":"sec-edgar","filing":"0000950170-25-043407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025043407/ownership.xml","form_type":"4"}},{"id":1194807,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-03-21T18:34:04.000Z","date":"2025-03-19","kind":"sale","planned":true,"acquired":false,"shares":2388,"price":34.17,"value":81597.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 1, 2023, and March 4, 2024. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $34.17 per share. The range of sales prices on the transaction date was $33.78 to $34.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":72360,"source":{"system":"sec-edgar","filing":"0000950170-25-043407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025043407/ownership.xml","form_type":"4"}},{"id":1249962,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-24T16:30:06.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025."}],"balance_after":65000,"derivative":{"exercise_price":36.86,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000950170-25-025665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025025665/ownership.xml","form_type":"4"}},{"id":1249961,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-02-24T16:30:06.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026."}],"balance_after":74748,"source":{"system":"sec-edgar","filing":"0000950170-25-025665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025025665/ownership.xml","form_type":"4"}},{"id":1282241,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2025-02-05T16:30:04.000Z","date":"2025-02-03","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":119042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-25-014557","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025014557/ownership.xml","form_type":"4"}},{"id":1282240,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-02-05T16:30:04.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":39.07,"value":195350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $39.07 per share. The range of sales prices on the transaction date was $38.89 to $39.49 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":31748,"source":{"system":"sec-edgar","filing":"0000950170-25-014557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025014557/ownership.xml","form_type":"4"}},{"id":1282239,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-02-05T16:30:04.000Z","date":"2025-02-03","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":16.89,"value":84450.0,"ownership":{"direct":true},"balance_after":36748,"source":{"system":"sec-edgar","filing":"0000950170-25-014557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025014557/ownership.xml","form_type":"4"}},{"id":1308364,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T16:30:08.000Z","date":"2025-01-07","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":18500,"derivative":{"exercise_price":19.64,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000950170-25-002869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025002869/ownership.xml","form_type":"4"}},{"id":1308363,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2025-01-07T16:30:08.000Z","date":"2025-01-03","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":124042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-002869","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025002869/ownership.xml","form_type":"4"}},{"id":1308362,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-01-07T16:30:08.000Z","date":"2025-01-07","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":19.64,"value":49100.0,"ownership":{"direct":true},"balance_after":31748,"source":{"system":"sec-edgar","filing":"0000950170-25-002869","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025002869/ownership.xml","form_type":"4"}},{"id":1308361,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-01-07T16:30:08.000Z","date":"2025-01-03","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":52.09,"value":781350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $52.09 per share. The range of sales prices on the transaction date was $51.60 to $52.60 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 741 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":29248,"source":{"system":"sec-edgar","filing":"0000950170-25-002869","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025002869/ownership.xml","form_type":"4"}},{"id":1308360,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2025-01-07T16:30:08.000Z","date":"2025-01-03","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":16.89,"value":253350.0,"ownership":{"direct":true},"balance_after":44248,"source":{"system":"sec-edgar","filing":"0000950170-25-002869","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017025002869/ownership.xml","form_type":"4"}},{"id":1390258,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-10-07T07:55:43.000Z","date":"2024-10-03","kind":"exercise","planned":true,"acquired":false,"shares":14375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":139042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":14375},"source":{"system":"sec-edgar","filing":"0000950170-24-113082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024113082/ownership.xml","form_type":"4"}},{"id":1390257,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-10-07T07:55:43.000Z","date":"2024-10-03","kind":"sale","planned":true,"acquired":false,"shares":14375,"price":54.63,"value":785306.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $54.63 per share. The range of sales prices on the transaction date was $53.53 to $55.29 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":28507,"source":{"system":"sec-edgar","filing":"0000950170-24-113082","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024113082/ownership.xml","form_type":"4"}},{"id":1390256,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-10-07T07:55:43.000Z","date":"2024-10-03","kind":"exercise","planned":true,"acquired":true,"shares":14375,"price":16.89,"value":242793.75,"ownership":{"direct":true},"balance_after":42882,"source":{"system":"sec-edgar","filing":"0000950170-24-113082","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024113082/ownership.xml","form_type":"4"}},{"id":1458951,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-07-05T16:30:02.000Z","date":"2024-07-03","kind":"exercise","planned":true,"acquired":false,"shares":14375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":153417,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":14375},"source":{"system":"sec-edgar","filing":"0000950170-24-081878","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024081878/ownership.xml","form_type":"4"}},{"id":1458950,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-07-05T16:30:02.000Z","date":"2024-07-03","kind":"sale","planned":true,"acquired":false,"shares":14375,"price":44.87,"value":645006.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.87 per share. The range of sales prices on the transaction date was $44.24 to $45.55 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 721 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":28507,"source":{"system":"sec-edgar","filing":"0000950170-24-081878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024081878/ownership.xml","form_type":"4"}},{"id":1458949,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-07-05T16:30:02.000Z","date":"2024-07-03","kind":"exercise","planned":true,"acquired":true,"shares":14375,"price":16.89,"value":242793.75,"ownership":{"direct":true},"balance_after":42882,"source":{"system":"sec-edgar","filing":"0000950170-24-081878","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024081878/ownership.xml","form_type":"4"}},{"id":1469673,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-06-25T17:03:15.000Z","date":"2024-06-24","kind":"exercise","planned":false,"acquired":false,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":167792,"derivative":{"exercise_price":19.73,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0000950170-24-077402","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024077402/ownership.xml","form_type":"4"}},{"id":1469672,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-06-25T17:03:15.000Z","date":"2024-06-24","kind":"sale","planned":false,"acquired":false,"shares":9500,"price":45.73,"value":434435.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $45.73 per share. The range of sales prices on the transaction date was $45.53 to $45.88 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":27786,"source":{"system":"sec-edgar","filing":"0000950170-24-077402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024077402/ownership.xml","form_type":"4"}},{"id":1469671,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-06-25T17:03:15.000Z","date":"2024-06-24","kind":"exercise","planned":false,"acquired":true,"shares":9500,"price":16.89,"value":160455.0,"ownership":{"direct":true},"balance_after":37286,"source":{"system":"sec-edgar","filing":"0000950170-24-077402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024077402/ownership.xml","form_type":"4"}},{"id":1540192,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock option (Right to Buy)","published_at":"2024-04-17T16:36:02.000Z","date":"2024-04-15","kind":"exercise","planned":true,"acquired":false,"shares":14375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":177292,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":14375},"source":{"system":"sec-edgar","filing":"0000950170-24-045142","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024045142/ownership.xml","form_type":"4"}},{"id":1540191,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-04-17T16:36:02.000Z","date":"2024-04-15","kind":"sale","planned":true,"acquired":false,"shares":14375,"price":44.47,"value":639256.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.47 per share. The range of sales prices on the transaction date was $43.98 to $44.75 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":27786,"source":{"system":"sec-edgar","filing":"0000950170-24-045142","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024045142/ownership.xml","form_type":"4"}},{"id":1540190,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-04-17T16:36:02.000Z","date":"2024-04-15","kind":"exercise","planned":true,"acquired":true,"shares":14375,"price":16.89,"value":242793.75,"ownership":{"direct":true},"balance_after":42161,"source":{"system":"sec-edgar","filing":"0000950170-24-045142","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000095017024045142/ownership.xml","form_type":"4"}},{"id":1563691,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-22T16:52:02.000Z","date":"2024-03-20","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":191667,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-24-005061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124005061/doc4.xml","form_type":"4"}},{"id":1563690,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-22T16:52:02.000Z","date":"2024-03-20","kind":"exercise","planned":false,"acquired":false,"shares":4375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":201667,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":4375},"source":{"system":"sec-edgar","filing":"0001209191-24-005061","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124005061/doc4.xml","form_type":"4"}},{"id":1563689,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-03-22T16:52:02.000Z","date":"2024-03-20","kind":"sale","planned":false,"acquired":false,"shares":714,"price":43.69,"value":31194.66,"ownership":{"direct":true},"balance_after":27786,"source":{"system":"sec-edgar","filing":"0001209191-24-005061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124005061/doc4.xml","form_type":"4"}},{"id":1563688,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-03-22T16:52:02.000Z","date":"2024-03-20","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":43.28,"value":432800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.28 per share. The range of sales prices on the transaction date was $42.70 to $43.77 per share.  Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":28500,"source":{"system":"sec-edgar","filing":"0001209191-24-005061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124005061/doc4.xml","form_type":"4"}},{"id":1563687,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-03-22T16:52:02.000Z","date":"2024-03-20","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":16.89,"value":168900.0,"ownership":{"direct":true},"balance_after":38500,"source":{"system":"sec-edgar","filing":"0001209191-24-005061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124005061/doc4.xml","form_type":"4"}},{"id":1563686,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-03-22T16:52:02.000Z","date":"2024-03-20","kind":"sale","planned":false,"acquired":false,"shares":4375,"price":45.89,"value":200768.75,"ownership":{"direct":true},"balance_after":28500,"source":{"system":"sec-edgar","filing":"0001209191-24-005061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124005061/doc4.xml","form_type":"4"}},{"id":1563685,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-03-22T16:52:02.000Z","date":"2024-03-20","kind":"exercise","planned":false,"acquired":true,"shares":4375,"price":16.89,"value":73893.75,"ownership":{"direct":true},"balance_after":32875,"source":{"system":"sec-edgar","filing":"0001209191-24-005061","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124005061/doc4.xml","form_type":"4"}},{"id":1566249,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-03-20T18:36:36.000Z","date":"2024-03-18","kind":"tax_withholding","planned":true,"acquired":false,"shares":411,"price":38.14,"value":15675.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 1, 2023.  The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":28500,"source":{"system":"sec-edgar","filing":"0001209191-24-005013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124005013/doc4.xml","form_type":"4"}},{"id":1592164,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-06T20:00:19.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":87000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024."}],"balance_after":87000,"derivative":{"exercise_price":43.51,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":87000},"source":{"system":"sec-edgar","filing":"0001209191-24-004607","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124004607/doc4.xml","form_type":"4"}},{"id":1592163,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-03-06T20:00:19.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025."}],"balance_after":28911,"source":{"system":"sec-edgar","filing":"0001209191-24-004607","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124004607/doc4.xml","form_type":"4"}},{"id":1688416,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2024-01-04T16:45:46.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":false,"shares":14375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":206042,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":14375},"source":{"system":"sec-edgar","filing":"0001209191-24-000816","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124000816/doc4.xml","form_type":"4"}},{"id":1688415,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-01-04T16:45:46.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":14375,"price":35,"value":503125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.00 per share. The range of sales prices on the transaction date was $34.82 to $35.32 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":5911,"source":{"system":"sec-edgar","filing":"0001209191-24-000816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124000816/doc4.xml","form_type":"4"}},{"id":1688414,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2024-01-04T16:45:46.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":true,"shares":14375,"price":16.89,"value":242793.75,"ownership":{"direct":true},"balance_after":20286,"source":{"system":"sec-edgar","filing":"0001209191-24-000816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919124000816/doc4.xml","form_type":"4"}},{"id":1701150,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2023-12-22T18:45:18.000Z","date":"2023-12-21","kind":"exercise","planned":false,"acquired":false,"shares":9583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":220417,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":9583},"source":{"system":"sec-edgar","filing":"0001209191-23-059628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919123059628/doc4.xml","form_type":"4"}},{"id":1701149,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2023-12-22T18:45:18.000Z","date":"2023-12-21","kind":"sale","planned":false,"acquired":false,"shares":9583,"price":34.57,"value":331284.31,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $34.57 per share. The range of sales prices on the transaction date was $34.50 to $34.67 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":5911,"source":{"system":"sec-edgar","filing":"0001209191-23-059628","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919123059628/doc4.xml","form_type":"4"}},{"id":1701148,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med and Dev Officer"}}],"security":"Common Stock","published_at":"2023-12-22T18:45:18.000Z","date":"2023-12-21","kind":"exercise","planned":false,"acquired":true,"shares":9583,"price":16.89,"value":161856.87,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,411 shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":15494,"source":{"system":"sec-edgar","filing":"0001209191-23-059628","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919123059628/doc4.xml","form_type":"4"}},{"id":1925438,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-04-05T19:12:46.000Z","date":"2023-04-05","kind":"sale","planned":true,"acquired":false,"shares":8212,"price":16.15,"value":132623.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $16.15 per share. The range of sales prices on the transaction date was $15.82 to $16.40 per share.  Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":4500,"source":{"system":"sec-edgar","filing":"0001209191-23-023469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919123023469/doc4.xml","form_type":"4"}},{"id":1925437,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-04-05T19:12:46.000Z","date":"2023-04-03","kind":"tax_withholding","planned":true,"acquired":false,"shares":4288,"price":15.98,"value":68522.24,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on September 30, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":12712,"source":{"system":"sec-edgar","filing":"0001209191-23-023469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919123023469/doc4.xml","form_type":"4"}},{"id":1974870,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T16:44:47.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 1, 2023."}],"balance_after":21000,"derivative":{"exercise_price":19.64,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-23-015609","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919123015609/doc4.xml","form_type":"4"}},{"id":1974869,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2023-03-03T16:44:47.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2024."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0001209191-23-015609","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919123015609/doc4.xml","form_type":"4"}},{"id":2139401,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-10-11T16:35:55.000Z","date":"2022-10-10","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":230000,"derivative":{"exercise_price":16.89,"expiration_date":"2032-10-09","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001209191-22-053313","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919122053313/doc4.xml","form_type":"4"}},{"id":2139400,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":72288,"kind":"person","name":"Pizzuti Dana","position":1,"cik":"0001948238","reported_name":"Pizzuti Dana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2022-10-11T16:35:55.000Z","date":"2022-10-10","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on March 30, 2023."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001209191-22-053313","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1948238/000120919122053313/doc4.xml","form_type":"4"}}]}